Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Armstrong

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Neurobiology of Disease|August 10, 2023
Role of TET1-mediated epigenetic modulation in Alzheimer's diseaseMatthew J Armstrong, Yulin Jin, Selina M Vattathil, et al.
Plos One|October 27, 2020
Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factorsJake P Mann, Paul Carter, Matthew J Armstrong, et al.
Frontiers in Physiology|March 4, 2022
Feasibility, Efficacy, and Safety of Percutaneous Muscle Biopsies in Patients With Chronic Liver DiseaseJonathan I Quinlan, Amritpal Dhaliwal, Felicity Williams, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 25, 2020
Sarcopenia in chronic liver disease: mechanisms and countermeasuresSophie L Allen, Jonathan I Quinlan, Amritpal Dhaliwal, et al.
The Journal of Clinical Endocrinology and Metabolism|February 22, 2013
Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivoJonathan M Hazlehurst, Laura L Gathercole, Maryam Nasiri, et al.
Journal of Hepatology|June 28, 2011
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohortMatthew J Armstrong, Diarmaid D Houlihan, Louise Bentham, et al.
Journal of Hepatology|September 23, 2015
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitisMatthew J Armstrong, Diana Hull, Kathy Guo, et al.
The Lancet. Gastroenterology & Hepatology|March 19, 2023
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialRohit Loomba, Manal F Abdelmalek, Matthew J Armstrong, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2019
Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent-shunt in patients with cirrhosisMatthew J Armstrong, Farhan Gohar, Amritpal Dhaliwal, et al.
BMJ Open|November 6, 2013
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trialMatthew J Armstrong, Darren Barton, Piers Gaunt, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Neurobiology of Disease|August 10, 2023
Role of TET1-mediated epigenetic modulation in Alzheimer's diseaseMatthew J Armstrong, Yulin Jin, Selina M Vattathil, et al.
Plos One|October 27, 2020
Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factorsJake P Mann, Paul Carter, Matthew J Armstrong, et al.
Frontiers in Physiology|March 4, 2022
Feasibility, Efficacy, and Safety of Percutaneous Muscle Biopsies in Patients With Chronic Liver DiseaseJonathan I Quinlan, Amritpal Dhaliwal, Felicity Williams, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 25, 2020
Sarcopenia in chronic liver disease: mechanisms and countermeasuresSophie L Allen, Jonathan I Quinlan, Amritpal Dhaliwal, et al.
The Journal of Clinical Endocrinology and Metabolism|February 22, 2013
Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivoJonathan M Hazlehurst, Laura L Gathercole, Maryam Nasiri, et al.
Journal of Hepatology|June 28, 2011
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohortMatthew J Armstrong, Diarmaid D Houlihan, Louise Bentham, et al.
Journal of Hepatology|September 23, 2015
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitisMatthew J Armstrong, Diana Hull, Kathy Guo, et al.
The Lancet. Gastroenterology & Hepatology|March 19, 2023
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialRohit Loomba, Manal F Abdelmalek, Matthew J Armstrong, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2019
Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent-shunt in patients with cirrhosisMatthew J Armstrong, Farhan Gohar, Amritpal Dhaliwal, et al.
BMJ Open|November 6, 2013
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trialMatthew J Armstrong, Darren Barton, Piers Gaunt, et al.
Pageof 12